[go: up one dir, main page]

MX2014001158A - Virus recombinantes de influenza porcina y usos del mismo. - Google Patents

Virus recombinantes de influenza porcina y usos del mismo.

Info

Publication number
MX2014001158A
MX2014001158A MX2014001158A MX2014001158A MX2014001158A MX 2014001158 A MX2014001158 A MX 2014001158A MX 2014001158 A MX2014001158 A MX 2014001158A MX 2014001158 A MX2014001158 A MX 2014001158A MX 2014001158 A MX2014001158 A MX 2014001158A
Authority
MX
Mexico
Prior art keywords
influenza virus
recombinant
methods
swine influenza
recombinant swine
Prior art date
Application number
MX2014001158A
Other languages
English (en)
Other versions
MX350283B (es
Inventor
Yan Zhou
Aleksandar Masic
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Publication of MX2014001158A publication Critical patent/MX2014001158A/es
Publication of MX350283B publication Critical patent/MX350283B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un virus quimérico, recombinante de influenza porcina que incluyen segmentos de hemaglutinina de más de un subtipo de virus influenza. También se describen métodos para producir los virus recombinantes de influenza, composiciones inmunogénicas que comprende los virus recombinantes de influenza, métodos para estimular una respuesta inmunitaria contra virus de influenza, y métodos para tratar y prevenir infección por virus de influenza.
MX2014001158A 2011-08-02 2012-07-31 Virus recombinantes de influenza porcina y usos del mismo. MX350283B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161514156P 2011-08-02 2011-08-02
PCT/CA2012/000717 WO2013016805A1 (en) 2011-08-02 2012-07-31 Recombinant swine influenza virus and uses thereof

Publications (2)

Publication Number Publication Date
MX2014001158A true MX2014001158A (es) 2014-07-14
MX350283B MX350283B (es) 2017-09-01

Family

ID=47628577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001158A MX350283B (es) 2011-08-02 2012-07-31 Virus recombinantes de influenza porcina y usos del mismo.

Country Status (11)

Country Link
US (2) US20130189303A1 (es)
EP (1) EP2739724B1 (es)
KR (1) KR102076794B1 (es)
CN (2) CN103764817A (es)
AU (1) AU2012289693B2 (es)
BR (1) BR112014002290B1 (es)
CA (1) CA2842872C (es)
DK (1) DK2739724T3 (es)
HK (1) HK1197268A1 (es)
MX (1) MX350283B (es)
WO (1) WO2013016805A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274806A1 (en) * 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
KR20170122786A (ko) * 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
WO2016168835A1 (en) 2015-04-17 2016-10-20 South Dakota Board Of Regents Compositions and methods for vaccination against influenza a virus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6090391A (en) 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CN101580849B (zh) 2000-04-28 2012-11-21 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
CA2437899C (en) 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
DK1499348T3 (en) * 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
WO2006083286A2 (en) 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
AU2007286161B2 (en) * 2006-08-09 2013-05-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8597661B2 (en) * 2007-05-04 2013-12-03 Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
WO2009092038A1 (en) * 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
JP5845180B2 (ja) * 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
RU2012107702A (ru) * 2009-07-31 2013-09-10 Пэксвэкс, Инк. Векторы на основе аденовирусов
WO2011056802A1 (en) * 2009-11-03 2011-05-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Influenza virus recombinant proteins

Also Published As

Publication number Publication date
AU2012289693B2 (en) 2017-02-02
EP2739724A4 (en) 2015-03-25
BR112014002290B1 (pt) 2021-11-03
US20130189303A1 (en) 2013-07-25
WO2013016805A1 (en) 2013-02-07
EP2739724A1 (en) 2014-06-11
CA2842872A1 (en) 2013-02-07
EP2739724B1 (en) 2018-08-15
CN106929486A (zh) 2017-07-07
MX350283B (es) 2017-09-01
CN103764817A (zh) 2014-04-30
US10098944B2 (en) 2018-10-16
CA2842872C (en) 2019-09-03
BR112014002290A2 (pt) 2017-02-21
KR102076794B1 (ko) 2020-02-12
HK1197268A1 (en) 2015-01-09
DK2739724T3 (en) 2018-11-26
US20170151323A1 (en) 2017-06-01
NZ620275A (en) 2016-03-31
KR20140047139A (ko) 2014-04-21
AU2012289693A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
EP4349404A3 (en) Respiratory virus vaccines
MX373884B (es) Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12013502442A1 (en) Inactivated dengue virus vaccine
HK1223301A1 (zh) 基於鼻内递送中和抗体以增强治疗效力的组合物和方法
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
PH12014500369A1 (en) Influenza h5 vaccines
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MX350283B (es) Virus recombinantes de influenza porcina y usos del mismo.
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.

Legal Events

Date Code Title Description
FG Grant or registration